Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) and Spruce Biosciences (NASDAQ:SPRB – Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, valuation, analyst recommendations and institutional ownership.
Profitability
This table compares Whitehawk Therapeutics and Spruce Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Whitehawk Therapeutics | N/A | -79.63% | -74.01% |
| Spruce Biosciences | N/A | -155.40% | -101.67% |
Institutional & Insider Ownership
52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by company insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Whitehawk Therapeutics | 1 | 1 | 4 | 0 | 2.50 |
| Spruce Biosciences | 1 | 2 | 7 | 0 | 2.60 |
Whitehawk Therapeutics presently has a consensus target price of $7.33, indicating a potential upside of 69.83%. Spruce Biosciences has a consensus target price of $163.00, indicating a potential upside of 218.86%. Given Spruce Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Spruce Biosciences is more favorable than Whitehawk Therapeutics.
Risk & Volatility
Whitehawk Therapeutics has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 3.11, meaning that its stock price is 211% more volatile than the S&P 500.
Valuation & Earnings
This table compares Whitehawk Therapeutics and Spruce Biosciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Whitehawk Therapeutics | N/A | N/A | -$20.60 million | ($1.68) | -2.57 |
| Spruce Biosciences | $4.91 million | 28.63 | -$38.97 million | ($36.60) | -1.40 |
Whitehawk Therapeutics has higher earnings, but lower revenue than Spruce Biosciences. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Spruce Biosciences beats Whitehawk Therapeutics on 7 of the 12 factors compared between the two stocks.
About Whitehawk Therapeutics
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
About Spruce Biosciences
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Receive News & Ratings for Whitehawk Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Whitehawk Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
